Cencora, Inc. $COR Stock Position Lessened by Strs Ohio

Strs Ohio lessened its position in Cencora, Inc. (NYSE:COR) by 26.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 53,678 shares of the company’s stock after selling 19,080 shares during the period. Strs Ohio’s holdings in Cencora were worth $16,776,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Cencora by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after buying an additional 1,125,661 shares during the last quarter. Geode Capital Management LLC lifted its stake in Cencora by 6.3% in the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after acquiring an additional 284,229 shares during the last quarter. Norges Bank acquired a new stake in Cencora in the second quarter valued at approximately $695,215,000. Viking Global Investors LP raised its holdings in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares in the last quarter. Finally, Amundi lifted its stake in shares of Cencora by 17.0% in the 2nd quarter. Amundi now owns 1,720,278 shares of the company’s stock valued at $500,893,000 after purchasing an additional 249,742 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president owned 23,891 shares in the company, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 20,316 shares of company stock valued at $7,151,265. 10.80% of the stock is currently owned by corporate insiders.

Cencora Stock Performance

Shares of NYSE:COR opened at $353.07 on Friday. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The business’s fifty day moving average price is $348.49 and its two-hundred day moving average price is $322.06. Cencora, Inc. has a fifty-two week low of $237.71 and a fifty-two week high of $377.54. The stock has a market capitalization of $68.49 billion, a price-to-earnings ratio of 44.41, a price-to-earnings-growth ratio of 1.68 and a beta of 0.66.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the company posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is presently 30.19%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on COR. Barclays initiated coverage on Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 target price on the stock. Evercore ISI set a $400.00 price target on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Robert W. Baird set a $415.00 price objective on Cencora in a research report on Tuesday, January 13th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $393.08.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.